Aromatherapy refers to the method of using the aromatic components of plants in appropriate forms to act on the entire body or a specific area to prevent and treat diseases. Essential oils used in aromatherapy are hydrophobic liquids containing volatile aromatic molecules， such as limonene， linalool， linalool acetate， geraniol， and citronellol. These chemicals have been extensively studied and shown to have a variety of functions， including reducing anxiety， relieving depression， promoting sleep， and providing pain relief. Terpenoids are a class of organic molecules with relatively low lipid solubility. After being inhaled， they can pass through the nasal mucosa for transfer or penetrate the skin and enter the bloodstream upon local application. Some of these substances also have the ability to cross the blood-brain barrier， thereby exerting effects on the central nervous system. Currently， the academic community generally agrees that products such as essential oils and aromatherapy from aromatic plants have certain health benefits. However， the process of extracting a single component from it and successfully developing it into a drug still faces many challenges. Its safety and efficacy still need to be further verified through more rigorous and systematic experiments. This article systematically elaborated on the efficacy of aromatic substances， including plant extracts and natural small molecule compounds， in antibacterial and antiviral fields and the regulation of nervous system activity. As a result， a deeper understanding of aromatherapy was achieved. At the same time， the potential of these aromatic substances for drug development was thoroughly explored， providing important references and insights for possible future drug research and application.

Objective: To explore the potential biological mechanism of chronic obstructive pulmonary disease (COPD) qi deficiency syndrome, we used the integrated pharmacology network computing platform and carried out experimental verification.Methods: Using an integrated pharmacology strategy to analyze the potential biological targets of COPD qi deficiency syndrome. Based on the established qi deficiency syndrome rat model of COPD, the bio-logical targets of lung and skeletal muscle were detected by electron microscopy, adenosine triphosphate (ATP) content assays, and western blotting. Results: According to the integrated pharmacological results, it was found that the locations of cell components related to COPD qi deficiency syndrome were mainly mitochondria. Electron microscopy results using lung tissue showed that mitochondria in the lipopolysaccharide (LPS group) and pulmonary instillation of LPS combined with cigarette smoke (LPS+CS group) were swollen, deformed, and frag-mented, with disappearing or broken crista. Results also showed that the total content of ATP in the lung and skeletal muscle of both groups was significantly lower than that in the control group at the 12th week (P<.05). At the 12th week, the expression of dynamin-related protein 1 (DRP1) and mitofusin 1 (MFN1) protein was significantly difference than that of the control group (P<.05). At the 10th and 14th weeks, changes in fission and fusion proteins in mitochondria of the lung and skeletal muscle were further detected. There was also a significant difference in the expression between the two groups compared to that in the control group at the 10th week and 14th week (P<.05). Conclusion: These findings suggest that the changes in mitochondrial morphology and ATP content and the unbalanced expression of DRP1 and MFN1 might be the key mechanisms underlying qi deficiency syndrome in rats with COPD.

From the view-point of a front-line research team in clinical laboratory medicine , the advantages of microfluidic technology and its prospect in the field of in vitro diagnosis ( IVD) were reviewed in this paper. This paper introduces the application of microfluidics in molecular diagnosis , immune detection and microbial pathogen testing , showing the value of this technology in meeting challenges posed by clinical laboratory medicine .Opportunities and challenges of microfluidic IVD technology under the new situation were also discussed.The authors believe this technology will play a great role in promoting the improvement of clinical laboratory technology .